Charles River buys Brains On-Line to extend CNS research reach

Charles River Laboratories International, Inc. has purchased Brains On-Line, a leading contract research organization (CRO) offering critical data that advances novel therapeutics for the treatment of central nervous system (CNS) diseases. Realizing the potential of drug development for central nervous system diseases, especially neurodegenerative disorders, Charles River is paying $21 million for Brains On-Line, a small-cap CRO with operations in San Francisco, the Netherlands and Germany that has preclinical contract research services in CNS and in vivo efficacy and pharmacokinetics testing for analysis of drugs in the brain. In addition to the initial purchase price, the transaction includes potential additional payments of up to $8 million based on future performance.

INC Research, inVentiv Health combination has net revenue exceeding $3 billion, psychiatry-focused site network

INC Research, inVentiv Health combination has net revenue exceeding $3 billion, psychiatry-focused site network

Raleigh-based contract research organization INC Research (Nasdaq: INCR) – which recently announced plans to merge with Boston-based inVentiv Health– has launched a new site network focused on psychiatry.

FDA Lays Out Work Plan for 21st Century Cures Act

In December 2016 Congress passed the 21st Century Cures Act as a bipartisan push to speed the creation and use of new medicines and therapeutic devices. Title III of the Cures Act provides funding to speed up the approval process. It adds $500 million over a decade to the Food & Drug Administration’s Innovation Account for this purpose.

Eli Lilly tries to offload midphase cancer compounds

In order to put its R&D budget into seven drug candidates that could become the new standard of care, Eli Lilly is looking for partners for six Phase 2 oncology candidates. “Lilly will pursue new standard-of-care changing therapies that target tumor dependencies in molecularly enriched populations, build rational combinations that overcome resistance and develop next-generation immunotherapies,” according to a company statement.

Cognitive Computing for Cancer: IBM's Watson Will Do Cancer Research

The New York Genome Center (NYGC) is partnering with IBM to analyze cancer-related genotypic and phenotypic data. The two companies have worked together since 2014 when they investigated glioblastomas, an aggressive brain tumor that kills more than 13,000 people per year. Now, as Nick Paul Taylor and Amirah Al Idris write in Fierce Biotech, they will be focusing on cancer as a whole.

CRA Demand on the Rise

CRA Demand on the Rise

Longer cycle times, complex protocols and CRA inexperience and turnover are cited as factors

At the same time as a global shortage of inexperienced Clinical Research Associates (CRAs) is projected, the demand for these professionals, who monitor clinical trials, is expected to grow 1.52 percent annually by 2018. According to Craig Morgan, writing in Center Watch News Online, one reason for the disparity is the lack of training opportunities. Instead of providing in-house training for new CRAs, many pharmaceutical companies have simply required that contract research organizations (CROs) have experienced CRAs on staff.

BIO 2017 Conference addresses biotech sector advances and challenges

BIO 2017 drew 16,123 biotech leaders from around the globe, hosted more than 41,400 partnering meetings and gave attendees unique perspectives on the great opportunities and complex challenges ahead for the biotech industry.  Held at the Convention Center in San Diego from June 19 to 22, BIO 2017 included over 1,800 exhibitors, more than 800 speakers at 400 educational sessions and company presentations and seven fireside chats.